Hemostatic Gauze Surgitamp and Granular Sorbent Molselect G-50 Application in the Treatment of Simulated Bleeding Liver Wounds

The aim of the study was to investigate the potential of Surgitamp hemostatic gauze and Molselect G-50 sorbent application in surgical hemostasis of simulated bleeding liver wounds in an in vivo experiment on laboratory animals.
Materials and methods. The study included 30 laboratory animals: Chinchilla rabbits. Laboratory animals underwent median laparotomy under intravenous anesthesia (Zoletil 100 – 0.1 ml /kg, Xylavet – 0.1 ml/kg), the right lobe of the liver was involved into the wound. At a 20 cm distance from the surface of the liver, a metal 92 g load in the form of a triangular prism was attached to the slider with the help of a thread. By operational readiness, the thread was burned, the prism fell vertically and hit the surface of the liver with a pointed end, this resulting in a simulated bleeding liver wound: a wound of the right lobe of the liver, linear in shape 3.0x0.7 cm, 0.6 cm deep, with uneven edges and active bleeding from the defect area. Hemostasis in the experimental group of animals (n=15) was carried out by covering the wound surface with a granular sorbent Molselect G-50, followed by tamponing the wound with a strip of hemostatic gauze Surgitamp. In the control group of animals (n=15) hemostasis was carried out by stitching a bleeding liver wound with a U-shaped suture with a PHA 3.0 thread until the edges of the wound converged. The effectiveness of hemostasis of the liver wounds was evaluated using the following parameters: the time of the final bleeding arrest, the volume of blood loss, the number of episodes of repeated bleeding.
Results. Experimental studies have demonstrated that the surgical hemostasis technique with the hemostatic agent Surgitamp application combined with the granular sorbent Molselect G-50 allows for reliable hemostasis of simulated bleeding liver wounds, reducing the time of bleeding arrest from 461.0(420.0-501.0) sec to 280.0(264.0-308.0) sec (P=0.0001), simultaneously reducing the incidence of recurrent hemorrhages from 46.7% to 6.7% (P=0.035).